InvestorsHub Logo
Followers 609
Posts 26741
Boards Moderated 1
Alias Born 08/12/2010

Re: gempicker post# 28644

Monday, 02/05/2018 11:06:26 PM

Monday, February 05, 2018 11:06:26 PM

Post# of 64359
You got it gem M&A on the way......

The company you reference is a 70 Billion dollar company. All Pharma stocks are flush with additional cash from tax cuts. Spending 100 or 200 million on a disruptive technology that can solve a significant medical crisis is a drop in the bucket..



from tax cuts and many have dollars overseas that will be coming back to the good ole U.S.

Who is in position with an incredible patented IP??? NUTRA PHARMA CORP.


Tax Overhaul Could Jolt Dollar as U.S. Companies Bring Home Cash

Corporations could repatriate as much as $400 billion in earnings and cash from abroad

https://www.wsj.com/articles/tax-overhaul-could-jolt-dollar-as-u-s-companies-bring-home-cash-1514206800

Mergers and acquisitions are anticipated to be huge with pharma and bio-techs...

Why 2018 is a make-or-break year for pharma

Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them

https://www.marketwatch.com/story/why-2018-is-a-make-or-break-year-for-pharma-2017-12-19

FROM ARTCILE:

This year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.

But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.

Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.

Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.

ALL POSTS are just my opinion! Never BUY/SELL stock based on only them! Perform your own DD and make your own decision!